TY  - JOUR
AU  - Chen, Tom Wei-Wu
AU  - Lin, Ching-Hung
AU  - Huang, Chiun-Sheng
PY  - 2016
TI  - Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
JF  - Translational Cancer Research; Vol 5, Supplement 4 (October 31, 2016): Translational Cancer Research
Y2  - 2016
KW  - 
N2  - The 2016 publication entitled “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial” in Lancet Oncology provided an opportunity to revisit the combination of pertuzumab and trastuzumab as a neoadjuvant treatment for HER2-positive breast cancer (1). Pertuzumab is the first Food and Drug Administration (FDA)-approved drug in the neoadjuvant setting (2).
UR  - https://tcr.amegroups.org/article/view/10172